ENG
Pulmonary Edema Market Industry Overview, Size, Share, Growth Trends, Research Insights and Forecast (2026–2032)
Pulmonary Edema Market size was valued at USD 7.11 bn in 2025, and the total Pulmonary Edema revenue is expected to grow at a CAGR of 7.8 % from 2026 to 2032, reaching nearly USD 12.03 bn by 2032.
Pulmonary Edema Market Overview
Pulmonary edema occurs when additional fluid accumulates in the lungs. The accumulation of fluid causes difficulty in breathing and increases pressure in the lungs, causing liquid leakage. Other factors responsible for fluid accumulation include infection, toxic risk and high height. Fulflene edema also increases the prevalence of heart diseases. According to the WHO, heart disease causes 16.8 million deaths annually. During COVID-19, the cases of pulmonary edema increased, especially in severe infections. SARS-CoV-2 causes fluid buildup. Recent developments in new drugs for pulmonary edema include sotolamide and cellubritil. Solnatide is a synthetic peptide. Solnatide helps to withdraw fluid from the sodium channel in the lungs. This syndrome is associated with COVID-19-related heart failure.
Sacubitril is used in combination with Valsartan, which prevents neprilysin enzymes. The NePlisin enzyme degraded the natural peptides. Sacubitril helps reduce the amount of blood and pressure, further reducing fluid accumulation in the lungs.
This innovation offers the option of existing drugs for managing pulmonary edema. Many major players include pulmonary edema treatment markets, especially in combination with Sacubitril and Valsartan. Lupine Limited received American approval for generic cobtril and Valstartan Tablet in January 2025. In addition, in September 2024, Biocon also received FDA approval for pulmonary edema drugs. Glenmark Pharmaceuticals in India began a 'Seku V' combination in January 2024 at an affordable rate.
To get more Insights: Request Free Sample Report
Pulmonary Edema Market Dynamics
Rising Prevalence of Cardiovascular Disease (CVDs) to Drive Pulmonary Edema Market
Heart disease is an important cause of mortality. According to the World Health Organization (WHO), heart disease is responsible for about 16.8 million deaths annually. These diseases include heart and blood vessel dissolution, coronary artery disease and many disorders of hypertension, leading to pulmonary edema. The World Health Organization (WHO) has emphasized that CVD deaths are caused by heart attacks and strokes, affecting one-third of a population of 70 years of age. The increasing proliferation of CVD has increased the demand for effective management strategies for complications such as pulmonary edema.
Increasing Incidence of Road Accidents Causing Chest Injuries to Drive the Pulmonary Edema Market
Contingency injuries are a major global health issue, causing about 1.19 million deaths each year. In particular, these injuries are 5–29 years old and are the major causes of death for young adults. Chest damage caused by such accidents can lead to acute respiratory complications, including pulmonary edema. The adequate economic burden of road traffic, with a cost of about 3% of its GDP, underlines the important need for advanced medical intervention to manage and reduce these health effects.
Aging Global Population and Increased Susceptibility to Grow Pulmonary Edema Market
Global demographic changes towards an older population have intensively implications for public health. Older individuals have a greater risk of developing heart and kidney conditions, which are primary risk factors for pulmonary edema. The WHO reports that in non-communicable diseases, including CVD, is low, and 75% of all deaths globally with middle-aged countries. As the elderly population increases, there is a need to demand an increase in incidence of age-related diseases, including pulmonary edema, an increase in health services and demand for driving in the pulmonary edema market.
Pulmonary Edema Market Segment Analysis
Based on Disease Type Pulmonary Edema Market is segmented into cardiogenic pulmonary edema and non-cardiogenic pulmonary edema. Cardiogenic pulmonary edema type leads the market. It is mainly associated with heart failure. According to Cleveland Clinic reports, about 6 million American adults have heart failure, and 80% of them experience pulmonary edema. Reports suggest that only 50% survive after one year of diagnosis, and 85% die within six years. Common causes include coronary artery disease, cardiomyopathy, and heart valve disorders. Treatment includes surgery, such as a diuretic, vasodilator, or bypass grafting and valve repair. Non-cardiogenic pulmonary edema is caused by lung injury, not due to heart problems. Conditions such as ARDS, infection, toxic breathing, or trauma can cause this. The Mayo Clinic states that high altitude risks can lead to high altitude pulmonary edema (HAPE), which may be life-threatening. Treatment focuses on oxygen therapy and, in severe cases, mechanical ventilation.
Based on Diagnosis Type Bottom of Forme, the Pulmonary Edema Market is segmented into imaging techniques and laboratory tests. Imaging techniques lead the pulmonary edema market. Chest X-ray is the most common imaging method for detecting fluid in the lungs, but the study suggests that CT scans provide more accurate results. Research also indicates that lung ultrasound, combined with deep learning techniques, can automatically assess the severity of pulmonary edema. Blood tests help evaluate oxygen levels and detect underlying conditions such as heart failure or infection. In cases of hantavirus pulmonary syndrome, laboratory results often show hemocytopenia, neutrophilic leukocytosis, and thrombocytopenia. A combination of imaging and laboratory tests allows initial diagnosis and better treatment results.
Based on Treatment Type, the Pulmonary Edema Market is segmented into oxygen therapy, medications, and surgical interventions. The pulmonary edema, which is characterized by fluid accumulation in the lungs, requires quick treatment to improve the results of the patient. Oxygen therapy is often the first line of treatment, which provides oxygen through face mask or nasal penetration to reduce symptoms. Medications play an important role; The diuretic helps to remove additional fluids by increasing the production of urine, while other drugs can increase heart function to prevent further liquid buildups. In severe cases, surgical intervention such as coronary artery bypass grafting or valve repair may require to address the underlying heart issues contributing to the pulmonary edema. According to WHO, more than 1 million patients are recruited annually with pulmonary edema for heart -related reasons. Early and proper treatment is necessary for people to reduce mortality and improve the quality of life.
Based on End User, the pulmonary edema market is segmented into hospitals and clinics, academic institutes, and ambulatory surgical centers. Hospitals and clinics are primary centers for the diagnosis and treatment of pulmonary edema. In the United States, acute cardiogenic pulmonary edema enters 1 million hospitals annually, causing about 6.5 million hospitalizations every year. In England and Wales, acute heart failure, a common cause of pulmonary edema, more than 67,000 hospital admissions per year. Acute pulmonary edema varies in the hospital mortality for patients; some studies have a reporting rate of 12% higher, and one-year mortality reaches 40%. According to the National Institute of Health (NIH), it conducted extensive research in pulmonary edema and acute lung injuries, supporting over 11,000 grants worth more than $ 600 million annually by 1970.
Pulmonary Edema Market Regional Analysis
North America
It shows dominance in the pulmonary edema market in 2025. North America is a well-developed healthcare sector, which has high per capita healthcare expenses. Global pulmonary edema dominates the market due to the presence of prominent players such as LifeSycense Corporation.In the United States, acute cardiogenic pulmonary edema accounts for around 1 million hospital admissions annually, accounting for about 6.5 million hospital admissions every year. In England and Wales, acute heart failure, a common cause of pulmonary edema, more than 67,000 hospital admissions per year. Acute pulmonary edema varies in the hospital mortality for patients; some studies have a reporting rate of 12% higher, and one-year mortality reaches 40%. These data outline the significant burden of pulmonary edema on the healthcare system and highlight the need for effective management and treatment strategies to suit regional health capabilities.
Pulmonary Edema Market Competitive Landscape
Many major players in the pulmonary edema treatment market facilitate progress in patient care. Among notable companies, Fizer Ink, Argon Medical, Edwards Life Sciences Corporation, BD (Bercin, Dickinson & Company), Medtronic, Koninklijke Philips NV, Siemens Healthier AG, Lupine Pahmasite Ink, Vitalttech Corporation, and Novartis AG. In recent developments, the Merc prevented its late-phase study of the pulmonary arterial hypertension drug due to strong efficacy data. This decision underlines the significant effect of the drug when the PAH -related mortality is reduced. Conversely, Kerose Therapeutics faced challenges when unexpected side effects suspended high doses in their lead drug tests for pulmonary artery hypertension.
Industry Consolidation:
|
Company |
Date
|
Type of Activity |
Description |
|
ResMed and Propeller Health |
April 2023 |
Acquisition |
ResMed acquired Propeller Health, enhancing its portfolio in remote patient monitoring and data-driven care management for respiratory diseases, including pulmonary edema. |
|
AstraZeneca and BioNTech |
March 2023 |
Collaboration |
AstraZeneca collaborated with BioNTech to develop novel immuno-oncology therapies, targeting conditions such as pulmonary edema associated with lung cancer. |
|
Novartis |
November 2023 |
FDA Approval |
Novartis received FDA approval for Entresto (sacubitril/valsartan) for treating heart failure with preserved ejection fraction (HFpEF), a condition that can lead to pulmonary edema. |
|
Verve Therapeutics |
September 2023 |
Clinical Trial Initiation |
Verve Therapeutics dosed the first patient in a Phase 1b clinical trial for VERVE-101, a potential gene therapy for pulmonary edema associated with pulmonary arterial hypertension. |
|
Pulmonary Edema Market Scope |
|
|
Market Size in 2025 |
USD 7.11 Bn. |
|
Market Size in 2032 |
USD 12.03 Bn. |
|
CAGR (2026-2032) |
7.8% |
|
Historic Data |
2020-2025 |
|
Base Year |
2025 |
|
Forecast Period |
2026-2032 |
|
Segments |
By Disease Type Cardiogenic Pulmonary Edema Non-Cardiogenic Pulmonary Edema |
|
By Diagnosis Imaging Techniques Laboratory Tests |
|
|
By Treatment Oxygen Therapy Medications Surgical Interventions |
|
|
By End-User Hospitals and Clinics Academic Institutes Ambulatory Surgical Centers |
|
|
Regional Scope |
North America- United States, Canada, and Mexico Europe – UK, France, Germany, Italy, Spain, Sweden, Russia, and the Rest of Europe Asia Pacific – China, India, Japan, South Korea, Australia, Taiwan, Philippines, Indonesia, Vietnam, Rest of APAC Middle East and Africa - South Africa, GCC, Egypt, Nigeria, Rest of the Middle East and Africa South America – Brazil, Argentina, Rest of South America |
Key Players in the Pulmonary Edema Market
North America
- Pfizer Inc. (USA)
- ARGON MEDICAL (USA)
- Edwards Lifesciences Corporation (USA)
- BD (Becton, Dickinson and Company) (USA)
- Abbott Laboratories (USA)
- Johnson & Johnson (USA)
- Merck & Co. (USA)
- GE Healthcare (USA)
- ResMed (USA)
- United Therapeutics Corporation (USA)
- Boehringer Laboratories (USA)
- Medtronic ( USA )
- AstraZeneca (UK)
Europe
- Bayer AG (Germany)
- Boehringer Ingelheim (Germany)
- Siemens Healthcare GmbH (Germany)
- Fresenius Medical Care (Germany)
- Novartis AG (Switzerland)
- Roche Holding AG (Switzerland)
- Actelion Pharmaceuticals Ltd. (Switzerland)
- Sanofi S.A. (France)
- Chiesi Farmaceutici (Italy)
- Koninklijke Philips N.V. (Netherlands)
- GlaxoSmithKline plc (UK)
Asia Pacific
- Lupin Pharmaceuticals (India)
- Hitachi Medical Corporation (Japan)
- Canon Medical Systems Corporation (Japan)
- Vitaltec Corporation (Taiwan)
Frequently Asked Questions
Key players include Pfizer Inc. and Edwards Lifesciences Corporation.
Heart disease weakens the heart, leading to fluid buildup in the lungs.
Coronary artery disease, hypertension, and heart failure can lead to pulmonary edema.
North America leads due to a strong healthcare sector and high per capita healthcare spending.
1. Pulmonary Edema Market Introduction
1.1. Study Assumption and Market Definition
1.2. Scope of the Study
1.3. Executive Summary
2. Global Pulmonary Edema Market: Competitive Landscape
2.1. SMR Competition Matrix
2.2. Key Players Benchmarking
2.2.1. Company Name
2.2.2. Service Segment
2.2.3. End-User Segment
2.2.4. Revenue (2024)
2.2.5. Geographical Presence
2.3. Market Structure
2.3.1. Market Leaders
2.3.2. Market Followers
2.3.3. Emerging Players
2.4. Mergers and Acquisitions Details
3. Pulmonary Edema Market: Dynamics
3.1. Pulmonary Edema Market Trends
3.2. Pulmonary Edema Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.2.4. Challenges
3.3. PORTER’s Five Forces Analysis
3.4. PESTLE Analysis
3.5. Regulatory Landscape by Region
3.6. Key Opinion Leader Analysis For the Global Industry
3.7. Analysis of Government Schemes and Initiatives for Industry
4. Pulmonary Edema Market: Global Market Size and Forecast by Segmentation (by Value in USD Million) (2025-2032)
4.1. Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
4.1.1. Cardiogenic Pulmonary Edema
4.1.2. Non-Cardiogenic Pulmonary Edema
4.2. Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
4.2.1. Imaging Techniques
4.2.2. Laboratory Tests
4.3. Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
4.3.1. Oxygen Therapy
4.3.2. Medications
4.3.3. Surgical Interventions
4.4. Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
4.4.1. Hospitals and Clinics
4.4.2. Academic Institutes
4.4.3. Ambulatory Surgical Centers
4.5. Pulmonary Edema Market Size and Forecast, By Region (2025-2032)
4.5.1. North America
4.5.2. Europe
4.5.3. Asia Pacific
4.5.4. Middle East and Africa
4.5.5. South America
5. North America Pulmonary Edema Market Size and Forecast by Segmentation (by Value in USD Million) (2025-2032)
5.1. North America Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
5.1.1. Cardiogenic Pulmonary Edema
5.1.2. Non-Cardiogenic Pulmonary Edema
5.2. North America Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
5.2.1. Imaging Techniques
5.2.2. Laboratory Tests
5.3. North America Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
5.3.1. Oxygen Therapy
5.3.2. Medications
5.3.3. Surgical Interventions
5.4. North America Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
5.4.1. Hospitals and Clinics
5.4.2. Academic Institutes
5.4.3. Ambulatory Surgical Centers
5.5. North America Pulmonary Edema Market Size and Forecast, by Country (2025-2032)
5.5.1. United States
5.5.1.1. United States Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
5.5.1.1.1. Cardiogenic Pulmonary Edema
5.5.1.1.2. Non-Cardiogenic Pulmonary Edema
5.5.1.2. United States Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
5.5.1.2.1. Imaging Techniques
5.5.1.2.2. Laboratory Tests
5.5.1.3. United States Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
5.5.1.3.1. Oxygen Therapy
5.5.1.3.2. Medications
5.5.1.3.3. Surgical Interventions
5.5.1.4. United States Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
5.5.1.4.1. Hospitals and Clinics
5.5.1.4.2. Academic Institutes
5.5.1.4.3. Ambulatory Surgical Centers
5.5.2. Canada
5.5.2.1. Canada Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
5.5.2.1.1. Cardiogenic Pulmonary Edema
5.5.2.1.2. Non-Cardiogenic Pulmonary Edema
5.5.2.2. Canada Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
5.5.2.2.1. Imaging Techniques
5.5.2.2.2. Laboratory Tests
5.5.2.3. Canada Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
5.5.2.3.1. Oxygen Therapy
5.5.2.3.2. Medications
5.5.2.3.3. Surgical Interventions
5.5.2.4. Canada Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
5.5.2.4.1. Hospitals and Clinics
5.5.2.4.2. Academic Institutes
5.5.2.4.3. Ambulatory Surgical Centers
5.5.3. Mexico
5.5.3.1. Mexico Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
5.5.3.1.1. Cardiogenic Pulmonary Edema
5.5.3.1.2. Non-Cardiogenic Pulmonary Edema
5.5.3.2. Mexico Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
5.5.3.2.1. Imaging Techniques
5.5.3.2.2. Laboratory Tests
5.5.3.3. Mexico Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
5.5.3.3.1. Oxygen Therapy
5.5.3.3.2. Medications
5.5.3.3.3. Surgical Interventions
5.5.3.4. Mexico Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
5.5.3.4.1. Hospitals and Clinics
5.5.3.4.2. Academic Institutes
5.5.3.4.3. Ambulatory Surgical Centers
6. Europe Pulmonary Edema Market Size and Forecast by Segmentation (by Value in USD Million) (2025-2032)
6.1. Europe Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
6.2. Europe Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
6.3. Europe Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
6.4. Europe Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
6.5. Europe Pulmonary Edema Market Size and Forecast, by Country (2025-2032)
6.5.1. United Kingdom
6.5.1.1. United Kingdom Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
6.5.1.2. United Kingdom Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
6.5.1.3. United Kingdom Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
6.5.1.4. United Kingdom Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
6.5.2. France
6.5.2.1. France Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
6.5.2.2. France Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
6.5.2.3. France Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
6.5.2.4. France Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
6.5.3. Germany
6.5.3.1. Germany Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
6.5.3.2. Germany Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
6.5.3.3. Germany Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
6.5.3.4. Germany Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
6.5.4. Italy
6.5.4.1. Italy Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
6.5.4.2. Italy Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
6.5.4.3. Italy Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
6.5.4.4. Italy Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
6.5.5. Spain
6.5.5.1. Spain Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
6.5.5.2. Spain Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
6.5.5.3. Spain Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
6.5.5.4. Spain Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
6.5.6. Sweden
6.5.6.1. Sweden Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
6.5.6.2. Sweden Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
6.5.6.3. Sweden Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
6.5.6.4. Sweden Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
6.5.7. Russia
6.5.7.1. Russia Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
6.5.7.2. Russia Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
6.5.7.3. Russia Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
6.5.7.4. Russia Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
6.5.8. Rest of Europe
6.5.8.1. Rest of Europe Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
6.5.8.2. Rest of Europe Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
6.5.8.3. Rest of Europe Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
6.5.8.4. Rest of Europe Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
7. Asia Pacific Pulmonary Edema Market Size and Forecast by Segmentation (by Value in USD Million) (2025-2032)
7.1. Asia Pacific Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
7.2. Asia Pacific Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
7.3. Asia Pacific Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
7.4. Asia Pacific Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
7.5. Asia Pacific Pulmonary Edema Market Size and Forecast, by Country (2025-2032)
7.5.1. China
7.5.1.1. China Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
7.5.1.2. China Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
7.5.1.3. China Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
7.5.1.4. China Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
7.5.2. S Korea
7.5.2.1. S Korea Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
7.5.2.2. S Korea Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
7.5.2.3. S Korea Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
7.5.2.4. S Korea Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
7.5.3. Japan
7.5.3.1. Japan Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
7.5.3.2. Japan Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
7.5.3.3. Japan Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
7.5.3.4. Japan Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
7.5.4. India
7.5.4.1. India Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
7.5.4.2. India Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
7.5.4.3. India Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
7.5.4.4. India Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
7.5.5. Australia
7.5.5.1. Australia Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
7.5.5.2. Australia Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
7.5.5.3. Australia Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
7.5.5.4. Australia Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
7.5.6. Indonesia
7.5.6.1. Indonesia Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
7.5.6.2. Indonesia Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
7.5.6.3. Indonesia Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
7.5.6.4. Indonesia Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
7.5.7. Malaysia
7.5.7.1. Malaysia Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
7.5.7.2. Malaysia Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
7.5.7.3. Malaysia Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
7.5.7.4. Malaysia Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
7.5.8. Philippines
7.5.8.1. Philippines Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
7.5.8.2. Philippines Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
7.5.8.3. Philippines Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
7.5.8.4. Philippines Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
7.5.9. Thailand
7.5.9.1. Thailand Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
7.5.9.2. Thailand Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
7.5.9.3. Thailand Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
7.5.9.4. Thailand Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
7.5.10. Vietnam
7.5.10.1. Vietnam Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
7.5.10.2. Vietnam Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
7.5.10.3. Vietnam Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
7.5.10.4. Vietnam Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
7.5.11. Rest of Asia Pacific
7.5.11.1. Rest of Asia Pacific Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
7.5.11.2. Rest of Asia Pacific Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
7.5.11.3. Rest of Asia Pacific Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
7.5.11.4. Rest of Asia Pacific Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
8. Middle East and Africa Pulmonary Edema Market Size and Forecast (by Value in USD Million) (2025-2032)
8.1. Middle East and Africa Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
8.2. Middle East and Africa Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
8.3. Middle East and Africa Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
8.4. Middle East and Africa Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
8.5. Middle East and Africa Pulmonary Edema Market Size and Forecast, by Country (2025-2032)
8.5.1. South Africa
8.5.1.1. South Africa Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
8.5.1.2. South Africa Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
8.5.1.3. South Africa Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
8.5.1.4. South Africa Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
8.5.2. GCC
8.5.2.1. GCC Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
8.5.2.2. GCC Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
8.5.2.3. GCC Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
8.5.2.4. GCC Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
8.5.3. Egypt
8.5.3.1. Egypt Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
8.5.3.2. Egypt Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
8.5.3.3. Egypt Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
8.5.3.4. Egypt Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
8.5.4. Nigeria
8.5.4.1. Nigeria Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
8.5.4.2. Nigeria Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
8.5.4.3. Nigeria Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
8.5.4.4. Nigeria Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
8.5.5. Rest of ME&A
8.5.5.1. Rest of ME&A Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
8.5.5.2. Rest of ME&A Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
8.5.5.3. Rest of ME&A Pulmonary Edema Market Size and Forecast, By Treatment(2025-2032)
8.5.5.4. Rest of ME&A Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
9. South America Pulmonary Edema Market Size and Forecast by Segmentation (by Value in USD Million) (2025-2032)
9.1. South America Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
9.2. South America Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
9.3. South America Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
9.4. South America Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
9.5. South America Pulmonary Edema Market Size and Forecast, by Country (2025-2032)
9.5.1. Brazil
9.5.1.1. Brazil Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
9.5.1.2. Brazil Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
9.5.1.3. Brazil Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
9.5.1.4. Brazil Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
9.5.2. Argentina
9.5.2.1. Argentina Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
9.5.2.2. Argentina Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
9.5.2.3. Argentina Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
9.5.2.4. Argentina Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
9.5.3. Colombia
9.5.3.1. Colombia Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
9.5.3.2. Colombia Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
9.5.3.3. Colombia Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
9.5.3.4. Colombia Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
9.5.4. Chile
9.5.4.1. Chile Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
9.5.4.2. Chile Pulmonary Edema Market Size and Forecast, By Diagnosis (2025-2032)
9.5.4.3. Chile Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
9.5.4.4. Chile Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
9.5.5. Rest Of South America
9.5.5.1. Rest Of South America Pulmonary Edema Market Size and Forecast, By Disease Type (2025-2032)
9.5.5.2. Rest Of South America Pulmonary Edema Market Size and Forecast, By Diagnosis(2025-2032)
9.5.5.3. Rest Of South America Pulmonary Edema Market Size and Forecast, By Treatment (2025-2032)
9.5.5.4. Rest Of South America Pulmonary Edema Market Size and Forecast, By End-User (2025-2032)
10. Company Profile: Key Players
10.1. Pfizer Inc. (USA)
10.1.1. Company Overview
10.1.2. Business Portfolio
10.1.3. Financial Overview
10.1.4. SWOT Analysis
10.1.5. Strategic Analysis
10.1.6. Recent Developments
10.2. ARGON MEDICAL (USA)
10.3. Edwards Lifesciences Corporation (USA)
10.4. BD (Becton, Dickinson and Company) (USA)
10.5. Abbott Laboratories (USA)
10.6. Johnson & Johnson (USA)
10.7. Merck & Co. (USA)
10.8. GE Healthcare (USA)
10.9. ResMed (USA)
10.10. United Therapeutics Corporation (USA)
10.11. Boehringer Laboratories (USA)
10.12. Medtronic ( USA )
10.13. AstraZeneca (UK)
10.14. Bayer AG (Germany)
10.15. Boehringer Ingelheim (Germany)
10.16. Siemens Healthcare GmbH (Germany)
10.17. Fresenius Medical Care (Germany)
10.18. Novartis AG (Switzerland)
10.19. Roche Holding AG (Switzerland)
10.20. Actelion Pharmaceuticals Ltd. (Switzerland)
10.21. Sanofi S.A. (France)
10.22. Chiesi Farmaceutici (Italy)
10.23. Koninklijke Philips N.V. (Netherlands)
10.24. GlaxoSmithKline plc (UK)
10.25. Lupin Pharmaceuticals (India)
10.26. Hitachi Medical Corporation (Japan)
10.27. Canon Medical Systems Corporation (Japan)
10.28. Vitaltec Corporation (Taiwan)
11. Key Findings
12. Industry Recommendations
13. Pulmonary Edema Market: Research Methodology
